Advanced Neuroendocrine Carcinoma Clinical Trial
Official title:
An Open-label, Multicenter Phase Ib/II Clinical Study to Evaluate the Safety and Efficacy of LBL-024 Combined With Etoposide and Platinum in the First-line Treatment of Patients With Advanced Neuroendocrine Carcinoma (NEC)
An open-label, multicenter phase Ib/II clinical study to evaluate the safety and efficacy of LBL-024 combined with etoposide and platinum in the first-line treatment of patients with advanced neuroendocrine carcinoma (NEC)
This trial includes two parts: phase Ib and phase II study. Phase Ib is a dose-escalation phase and Phase II is a dose-expansion phase. Phase Ib program to enroll patients with advanced neuroendocrine carcinoma (NEC) without systemic therapy. To sequentially evaluate the safety and tolerability of LBL-024 in combination with etoposide and platinum (cisplatin or carboplatin) at different doses by the dose-escalation method. Phase II program to enroll approximately 50 patients with advanced neuroendocrine carcinoma without systemic treatment. This trial will enroll 68 patients in Phase Ib and Phase II study. ;